Hemoglobinopathies are a genetic disorder caused due to structural abnormality in the hemoglobin molecule. Specifically due to defective globin chain. This genetic disorder falls into two main types, which include Thalassemia and Sickle cell disease. Thalassemia is a blood disorder occurs due to the inadequate amount of hemoglobin. Due to this disorder, a large number of red blood cells get destroyed and further leads to anemia. Sickle cell disease is hemoglobin related disease in which patients with this condition have atypical hemoglobin molecule called haemoglobin-S, it can destroy red blood cells into a sickle. These diseases do not have any cure. India is the home for the hemoglobinopathies for an instance in India there are over 150,000 patients with thalassemia which is higher than others. As this disorder have no cure research & development in treatment of this disorder is necessary. Few key players which are working on the development are Gamilda Cell, Alnylam Pharmaceuticals, Cancer Therapeutics CRC Pty Ltd, and others. All these companies are investing a huge amount on the development of the cure for Hemoglobinopathies. Common therapies available for an instant are bone marrow transplant, blood transfusion, chelation therapy, and others. Hemoglobinopathies Market accounted 6.4 USD billion in 2020 and is expected to reach 17 USD billion by 2030 growing with a CAGR of 10.2% during the forecast period.

Market Segmentation:

On the basis of type, the hemoglobinopathies market is segmented into thalassemia and sickle cell disease. On th0e basis of therapy, the market is segmented into blood transfusion and iron chelation therapy. On the basis of the test, the market is segmented into a red blood cell count test and genetic test. By region, the hemoglobinopathies market is segmented into North America, Europe, Asia Pacific, and RoW.

Market Dynamics and Factors:

The rising need for the prevention of the hemoglobin disorders which includes sickle cell, anemia is one of the major drivers of the market. According to the World Health Organisation (WHO), hemoglobin disorders are original endemic disease occurs 60% of the 229 countries affecting over 70% of the births. Increasing investments in the development of therapies within emerging countries will boost the hemoglobinopathies market in the upcoming years. Well established and growing healthcare sectors in emerging countries will propel the market. Growing awareness among the populace will further support the growth of the hemoglobinopathies market. However, unavailability of the treatment in less developed regions and unawareness about disorder in some regions hinder the hemoglobinopathies market growth. The development of new therapies and low-cost treatment will further create opportunities in the hemoglobinopathies market.

Geographic Analysis:

North America is the dominating region and expected to continue its supremacy in the upcoming years with the highest investment in R & D activity. In 2015 North America was the highest revenue-generating region with approximately 1.2 billion USD owing to the growth and increase in the R and D investments. Asia Pacific is also expected to witness rapid growth due to the rapidly increasing awareness of hemoglobin related diseases. In addition to that development of the low-cost diagnostic kit for the hemoglobinopathy will further contribute to growth. The market is expected to grow with a CAGR of 6% during the forecast period. The Middle East and Africa are also suffering from this disorder, in West Africa; almost 20% of the populace has Sickle cell disorder and around 2% of babies born with the disorder. Hemoglobinopathies market in Europe is also growing with significant growth. Few regions in Europe are considered to be Hemoglobinopathy prevalent region.

Competitive Scenario:

Key market players in the hemoglobinopathies market include Alnylam Pharmaceuticals; Sangamo Therapeutics Inc.; Sanofi; Global Blood Therapeutics; bluebird bio Inc.; Gamida Cell; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation.

Hemoglobinopathies Market Report Scope

Report Attribute	Details
Analysis Period	2020–2030
Base Year	2021
Forecast Period	2022–2030
Market Size Estimation	Billion (USD)
Growth Rate (CAGR%)	12.2 %
Market Segmentation:	By Type (Thalassemia and Sickle Cell Disease), By Therapy (Blood Transfusion and Iron Chelation Therapy), By Test (Red Blood Cell Count Test and Genetic Testing)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, France, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), South America (Brazil, Argentina, Rest of SA), MEA (UAE, Saudi Arabia, South Africa)
Key Companies Profiled	Alnylam Pharmaceuticals; Sangamo Therapeutics Inc.; Sanofi; Global Blood Therapeutics; bluebird bio Inc.; Gamida Cell; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation.